Poster presentation details are as follows:
-- First-Line Treatment of Hormone Refractory Prostate Cancer: Abstract
A Phase 2 study of picoplatin with docetaxel and prednisone in
chemotherapy-naive patients with metastatic hormone-refractory
prostate cancer (HRPC)
Roman L, Karlov P, Cheporov S, Lopatkin N, Breitz H, Karlin D, Baker G.
General Poster Session: Saturday, May 31, from 8 a.m. to 12 p.m. CDT
S Hall A1, Poster #16A
-- First-line Treatment of Colorectal Cancer: Abstract #4100
First-line Phase 1b and 2 studies of picoplatin in combination with
5-fluorouracil and leucovorin, FOLPI, as a potential
neuropathy-sparing therapy for colorectal cancer
Cheporov S, Gladkov O, Biakhov M, Breitz H, Karlin D, Baker G.
General Poster Session: Monday, June 2, from 8 a.m. to 12 p.m. CDT
S Hall A1, Poster #14B
In addition, Don S. Dizon, M.D., assistant professor of
obstetrics-gynecology and medicine at the Warren Alpert Medical School of
Brown University, will present data from a Phase 1 trial of picoplatin in
patients with ovarian cancer:
-- Phase 1 Combination Study with Pegylated Liposomal Doxorubicin
(including Ovarian Cancer): Abstract #2568,
Final results of a Phase 1 study of picoplatin and pegylated liposomal
doxorubicin in advanced solid tumor malignancies
Dizon DS, Maluf F, Aghajanian CA, Daud A, Sabbatini P, Soignet S,
Pezzulli S and Spriggs DR.
General Poster Session: Sunday, June 1, from 2 p.m. to 6:00 p.m. CDT
S Hall A1, Poster #12H
Poniard Investor Event
In addition to the picoplatin
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved